Welcome to our dedicated page for Palatin Tech news (Ticker: PTN), a resource for investors and traders seeking the latest updates and insights on Palatin Tech stock.
Palatin Technologies, Inc. (PTN) generates a steady flow of news as a biopharmaceutical company centered on melanocortin receptor–based therapeutics. News coverage for PTN often highlights updates on its obesity, ocular, and retinal programs, as well as financing events and stock listing developments. Investors and followers can use this page to review how Palatin’s scientific, clinical, and corporate milestones evolve over time.
Recent press releases have focused on obesity program progress, including preclinical and clinical data for the oral MC4R agonist PL7737 and next-generation peptide MC4R agonists. Palatin has reported robust weight loss and favorable safety in preclinical models, Phase 2 data on co-administration of an MC4R agonist with tirzepatide in obese patients, and regulatory designations such as Orphan Drug status for PL7737 in LEPR deficiency–related obesity. These updates provide insight into the company’s efforts to develop mechanism-based obesity therapies.
Palatin news also covers its ocular and retinal pipeline. Releases describe Phase 3 MELODY-1 data for PL9643 in dry eye disease, including responder analyses showing complete symptom resolution across multiple endpoints, and preclinical findings for PL9654 and PL9655 in diabetic retinopathy that demonstrate inflammation resolution, vascular stabilization, and neuroprotection. Announcements related to the company’s collaboration with Boehringer Ingelheim for retinal diseases further illustrate how Palatin seeks to advance its melanocortin platform through partnerships.
On the corporate side, PTN news items detail public offerings, warrant structures, and exchange listing status, including NYSE American delisting proceedings, trading on OTC markets, a 1-for-50 reverse stock split, and the subsequent resumption of trading on NYSE American. For readers tracking PTN, this news feed brings together scientific presentations, clinical trial readouts, collaboration agreements, and capital markets activity in one place, making it easier to follow Palatin’s development trajectory and key disclosures.
Palatin Technologies (NYSE American: PTN) has completed a favorable End-of-Phase 2 meeting with the FDA regarding PL9643 for treating dry eye disease (DED). The FDA and Palatin agreed on key elements for a pivotal Phase 3 clinical program, including study design and patient population. The Phase 3 study is set to begin in Q4 2021, with data expected in H2 2022 and a potential NDA submission in H2 2023. Previous Phase 2 results showed significant improvement in DED symptoms with no safety concerns.
Palatin Technologies, Inc. (NYSE American: PTN) has appointed three key executives to strengthen its leadership team. Michael B. Raizman, M.D. is now Chief Medical Officer, James E. Hattersley is Senior Vice President of Business Development, and J. Don Wang, Ph.D. is Vice President of Product Development. These appointments aim to enhance Palatin's capabilities in advancing its inflammatory and autoimmune programs. The new executives bring extensive experience in medical, business development, and product research, expected to aid the company in navigating market challenges effectively.
Palatin Technologies (PTN) announced the adjournment of its 2021 Annual Meeting of Stockholders from June 8 to July 8, 2021, to gather more proxies for Proposal 3, which seeks to increase the authorized common stock from 300 million to 400 million shares. Currently, approximately 69% of votes on Proposal 3 support the measure, but it lacks an absolute majority. The Board believes this increase is necessary for future flexibility and potential strategic opportunities. Shares must be voted before July 7, 2021, 11:59 PM EDT to be counted.
Palatin (PTN) reported third-quarter results for the period ending March 31, 2021, showing significant growth across its product Vyleesi, with gross sales increasing by 89% and net revenue rising by 154% compared to the previous quarter. The company plans to initiate a Phase 3 trial for PL9643 in dry eye disease and a Phase 2 study for PL8177 in ulcerative colitis, both expected in the second half of 2021. As of March 31, 2021, Palatin held $68.6 million in cash. Despite a net loss of $5.7 million, the company highlighted improving prescription trends and insurance coverage, boosting optimism moving forward.
Palatin Technologies, Inc. (NYSE American: PTN) announced a KOL webinar focusing on melanocortin agonists for ocular indications, particularly PL9643 for dry eye disease (DED). Scheduled for May 21, 2021, the webinar will feature experts discussing the biological underpinnings and clinical development of PL9643. A Phase 3 study for PL9643 is anticipated in the latter half of 2021. The event aims to showcase the company's advancements in treating eye inflammation and highlight the unmet medical needs in this field.
Palatin Technologies (NYSE American: PTN) will announce its Q3 fiscal year 2021 operating results on May 17, 2021, before the U.S. markets open. A conference call, led by the executive management team, is scheduled for the same day at 11:00 a.m. ET to discuss the results and provide updates on ongoing programs. The results will be released at 7:30 a.m. ET.
Investors can access the audio webcast and replay through the Investors-Webcasts section on the company's website.
Palatin Technologies (PTN) announced that the USPTO granted a 5-year patent term extension for one of its patents covering Vyleesi® (bremelanotide injection), now set to expire on June 25, 2025. Vyleesi is the only FDA-approved on-demand treatment for hypoactive sexual desire disorder (HSDD) in premenopausal women. The extension is in line with the Hatch-Waxman Amendments, compensating for time lost during drug development and FDA review. Additional patents related to methods of treating HSDD are valid until November 2033.
Palatin Technologies, Inc. (NYSE American: PTN) announced two presentations at the virtual ARVO 2021 Annual Meeting, occurring from May 1-7, 2021. The presentations will showcase clinical data for PL9643, a melanocortin agonist, focusing on its potential in treating dry eye disease and ocular inflammation. CEO Carl Spana emphasized the therapeutic promise of melanocortins in inflammatory conditions during the event. Presentations are set for May 1 and May 6, covering efficacy and safety studies and protective effects in ocular disease models, respectively.
Palatin Technologies (NYSE American: PTN) will participate in the H.C. Wainwright Global Life Sciences Virtual Conference on March 9-10, 2021. CEO Carl Spana will present, with the presentation available for on-demand viewing starting March 9, 2021, at 7:00 a.m. ET. It will remain accessible on Palatin's Investor page for 30 days. The company focuses on developing first-in-class medicines targeting melanocortin peptide receptor systems, addressing significant medical needs.
Palatin Technologies (PTN) reported a net loss of $10.0 million, or $0.04 per share, for the second quarter ended December 31, 2020, compared to a loss of $5.2 million, or $0.02 per share, in Q2 2019. The increase in loss is primarily due to commercial expenses for Vyleesi and ongoing Phase 2 trials for PL9643. Vyleesi gross sales reached $943,950, with product revenue at -$163,971. However, the company announced positive results for PL9643 in treating dry eye disease, with the next Phase 2/3 trial set for mid-2021.
FAQ
What is the current stock price of Palatin Tech (PTN)?
What is the market cap of Palatin Tech (PTN)?
